Bristol-Myers Squibb Company Profile (NYSE:BMY)

About Bristol-Myers Squibb

Bristol-Myers Squibb logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: BMY
  • CUSIP: 11012210
Key Metrics:
  • Previous Close: $50.36
  • 50 Day Moving Average: $54.16
  • 200 Day Moving Average: $65.90
  • 52-Week Range: $49.10 - $77.12
  • Trailing P/E Ratio: 29.45
  • Foreward P/E Ratio: 17.37
  • P/E Growth: 1.08
  • Market Cap: $84.14B
  • Outstanding Shares: 1,670,858,000
  • Beta: 0.74
  • Net Margins: 16.63%
  • Return on Equity: 24.92%
  • Return on Assets: 11.53%
  • Debt-to-Equity Ratio: 0.44%
  • Current Ratio: 1.56%
  • Quick Ratio: 1.38%
Additional Links:
Companies Related to Bristol-Myers Squibb:

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb (NYSE:BMY) (?)
Ratings Breakdown: 2 Sell Ratings, 11 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.29)
Consensus Price Target: $67.67 (34.37% upside)

Analysts' Ratings History for Bristol-Myers Squibb (NYSE:BMY)
DateFirmActionRatingPrice TargetDetails
10/17/2016Credit Suisse Group AGReiterated RatingHold$58.00View Rating Details
10/13/2016Goldman Sachs Group Inc.DowngradeStrong-Buy -> Buy$75.00View Rating Details
10/12/2016Barclays PLCReiterated RatingEqual WeightView Rating Details
10/10/2016SunTrust Banks Inc.Reiterated RatingHold$68.00 -> $62.00View Rating Details
10/9/2016Leerink SwannReiterated RatingOutperform$69.00View Rating Details
9/20/2016Citigroup Inc.Lower Price TargetBuy$75.00 -> $70.00View Rating Details
9/12/2016Jefferies GroupReiterated RatingHold -> Hold$69.00 -> $57.00View Rating Details
9/3/2016BMO Capital MarketsReiterated RatingMarket Perform$60.00View Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldView Rating Details
8/13/2016ArgusReiterated RatingBuy$90.00View Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00View Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00View Rating Details
8/10/2016William BlairReiterated RatingBuyView Rating Details
8/8/2016Piper Jaffray Cos.Reiterated RatingNeutral$69.00 -> $65.00View Rating Details
8/8/2016Deutsche Bank AGLower Price TargetHold$68.00 -> $62.00View Rating Details
5/23/2016Hilliard LyonsInitiated CoverageNeutralView Rating Details
5/19/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00View Rating Details
12/14/2015Cowen and CompanyReiterated RatingOutperform$75.00 -> $100.00View Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00View Rating Details
11/28/2014FBR & CoReiterated RatingPositiveView Rating Details
10/27/2014MKM PartnersBoost Price TargetSell$34.00 -> $36.00View Rating Details
(Data available from 10/21/2014 forward)


Earnings History for Bristol-Myers Squibb (NYSE:BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016Q316$0.64$4.76 billionN/AView Earnings Details
7/28/2016Q216$0.66$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.41$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bristol-Myers Squibb (NYSE:BMY)
Current Year EPS Consensus Estimate: $2.63 EPS
Next Year EPS Consensus Estimate: $2.9 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.63$0.66$0.64
Q2 20164$0.65$0.69$0.67
Q3 20164$0.61$0.67$0.64
Q4 20163$0.57$0.61$0.59
Q1 20171$0.74$0.74$0.74
Q2 20171$0.80$0.80$0.80
Q3 20171$0.84$0.84$0.84
Q4 20171$0.86$0.86$0.86
(Data provided by Zacks Investment Research)


Current Dividend Information for Bristol-Myers Squibb (NYSE:BMY)
Annual Dividend:$1.52
Dividend Yield:3.02%
Dividend Growth:2.90% (3 Year Average)
Payout Ratio:87.36% (Based on Trailing 12 Months of Earnings)
57.79% (Based on Current Year Consensus EPS Estimate)
52.41% (Based on Next Year Consensus EPS Estimate)
Track Record:6 Years of Consecutive Dividend Growth

Dividend History for Bristol-Myers Squibb (NYSE:BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Bristol-Myers Squibb (NYSE:BMY)
Insider Ownership Percentage: 0.24%
Institutional Ownership Percentage: 72.87%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Bristol-Myers Squibb (NYSE:BMY)
News IconReg Filings: As Bristol Myers Squibb Co (BMY) Shares Rose, Shareholder Castleark Management LLC Has Increased ... - Chester News (NYSE:BMY) - October 20 at 8:47 PM logoDefining the True Value of Innovation in Cancer Treatment (NYSE:BMY) - October 20 at 3:24 PM
News IconAnalysts Advise About: Bristol-Myers Squibb Company (NYSE:BMY) - The Independent Republic (NYSE:BMY) - October 20 at 9:46 AM
News IconTop Gainers of the Day: Bristol-Myers Squibb Company (NYSE:BMY) from Drug Manufacturers – Major (NYSE:BMY) - October 19 at 4:44 PM logo3 Reasons Bristol-Myers Is a Buy (NYSE:BMY) - October 19 at 4:44 PM logoBristol-Myers Squibb Co. : BMY-US: Dividend Analysis : October 07th, 2016 (record date) : By the numbers : October 19, 2016 (NYSE:BMY) - October 19 at 4:44 PM logoAnalysts EPS Target At $0.64 For Bristol-Myers Squibb Company (NYSE:BMY) - Stocks Daily (NYSE:BMY) - October 18 at 3:52 PM
News Icon2 Stocks Analyst-Opinion Need Close Attention: Bristol-Myers Squibb (BMY), Citizens Financial (CFG) - The Voice Registrar (NYSE:BMY) - October 18 at 8:43 AM
News IconStock Perspective: Bristol-Myers Squibb Company (NYSE:BMY) Earnings in View - CSZ News (NYSE:BMY) - October 17 at 3:49 PM
News IconInvestor's Watch: Bristol-Myers Squibb Co (NYSE:BMY) - Post Registrar (NYSE:BMY) - October 17 at 3:49 PM logoBristol-Myers Squibb Foundation Joins White House Cancer Moonshot (NYSE:BMY) - October 17 at 3:49 PM logoThe Time Is Right to Pick Up Bristol-Myers Squibb (NYSE:BMY) - October 17 at 3:49 PM logoPfizer and Bristol-Myers Squibb Could Face a Big Threat from Small Biotech Exelixis (NYSE:BMY) - October 17 at 8:46 AM
News IconDrug Manufacturers – Major: Bristol-Myers Squibb Company (NYSE:BMY) Position of the day (NYSE:BMY) - October 16 at 8:41 AM logoStock Update (NYSE:BMY): Bristol-Myers Squibb Co Receives Positive CHMP Opinion for Opdivo (NYSE:BMY) - October 16 at 8:41 AM
News IconNokia Corp (ADR) (NYSE:NOK) & Bristol-Myers Squibb Co (NYSE:BMY) Watch List - Money News (NYSE:BMY) - October 15 at 3:49 PM logo3 Incredibly Cheap Big Pharma Stocks (NYSE:BMY) - October 15 at 7:54 AM logoStock Update (NYSE:BMY): Bristol-Myers Squibb Co Receives Positive CHMP Opinion for Opdivo - Smarter Analyst (NYSE:BMY) - October 14 at 12:20 PM logoBristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedot (NYSE:BMY) - October 14 at 12:20 PM
News IconBullish Movers Gaining Investors Attention: Bristol-Myers Squibb Company (NYSE:BMY), Eli Lilly and Company (NYSE ... - Street Wise Report (press release) (blog) (NYSE:BMY) - October 13 at 9:06 PM logoBristol-Myers Asked to Seek Special Coverage for Opdivo in U.K. (NYSE:BMY) - October 13 at 9:06 PM
News IconHigh Market Cap Stock of the Day – Bristol-Myers Squibb Company (NYSE:BMY) (NYSE:BMY) - October 13 at 3:47 PM logoBristol-Myers (BMY) Stock Removed From Goldman's 'Conviction Buy' List (NYSE:BMY) - October 13 at 3:47 PM logoBristol-Myers Squibb Company Co (BMY) Ownership Down in Latest Report from Legal & General Group Plc (NYSE:BMY) - October 12 at 9:16 PM
News IconBristol-Myers Squibb Co (NYSE:BMY) Analyst Research Summary (NYSE:BMY) - October 12 at 9:16 PM logoResearch Reports on Drug Makers Equities -- Bristol-Myers Squibb, AstraZeneca, TherapeuticsMD, and Impax ... - PR Newswire (press release) (NYSE:BMY) - October 12 at 4:07 PM
News IconStock on Analyst Radar: Bristol-Myers Squibb Co (NYSE:BMY) - Post Registrar (NYSE:BMY) - October 12 at 4:07 PM logo9:53 am Bristol-Myers displays Relative Strength with a strong rally over yesterday's highs for a +2% gain (NYSE:BMY) - October 12 at 4:07 PM logoBMY’s Drug Treatments That Go beyond Immuno-Oncology (NYSE:BMY) - October 12 at 4:07 PM logoBristol-Myers Shares Plunge 7% as Lung Cancer Drug Fails Again - ETF Daily News (blog) (NYSE:BMY) - October 12 at 8:19 AM logoBristol-Myers Squibb: The Opdivo Fiasco - Seeking Alpha - Seeking Alpha (NYSE:BMY) - October 12 at 8:19 AM
News Icon3 Additions to the Wide Moat Focus Index (NYSE:BMY) - October 12 at 8:19 AM logoHow Large of a Role Does Opdivo Play in Bristol-Myers Squibb’s Success? (NYSE:BMY) - October 12 at 8:19 AM logoInvestor Movement Index for September 2016 - Benzinga (NYSE:BMY) - October 11 at 3:57 PM logoBristol-Myers Squibb: The Opdivo Fiasco - Seeking Alpha (NYSE:BMY) - October 11 at 3:57 PM logoBristol-Myers Squibb’s Strategies to Dominate Immuno-Oncology Market (NYSE:BMY) - October 11 at 3:57 PM logoHow Bristol-Myers Squibb Is Expanding Its Lung Cancer Treatments (NYSE:BMY) - October 11 at 3:57 PM logoBMY Waiting to Enter the First-Line Lung Cancer Space (NYSE:BMY) - October 11 at 3:57 PM logoBristol-Myers Partner Ono Drops as Cancer Drug Data Disappoint - Bloomberg (NYSE:BMY) - October 10 at 10:13 PM logoBristol-Myers shares fall 10% after cancer treatment disappoints (NYSE:BMY) - October 10 at 5:35 PM logoCheckMate Again for Bristol-Myers Squibb Co. As Shares Dip 10% (NYSE:BMY) - October 10 at 4:13 PM
News IconEnergy Stocks Lead Market Higher; Bristol-Myers Plunges, Merck Rises (NYSE:BMY) - October 10 at 3:49 PM logoBristol-Myers Squibb (BMY) Announces Statistically Significant Data from Opdivo Phase 3 in Squamous Cell Carcinoma - (NYSE:BMY) - October 10 at 3:47 PM
News IconWorth Watching Stocks in Focus: Facebook Inc(NASDAQ:FB), Bristol-Myers Squibb Co(NYSE:BMY), Wal-Mart Stores ... - NYSE Journal (press release) (NYSE:BMY) - October 10 at 3:47 PM logoBristol-Myers Squibb (BMY) Presents Strong Data from Opdivo + Yervoy Combo Phase 1 in mRCC - (NYSE:BMY) - October 10 at 3:47 PM logoBristol-Myers Squibb Enters Oversold Territory - Nasdaq (NYSE:BMY) - October 10 at 3:47 PM logo3 Stocks to Watch Monday: Mylan NV (MYL), Bristol-Myers Squibb Co (BMY) and Comcast Corporation (CMCSA) - (NYSE:BMY) - October 10 at 3:47 PM logoBristol-Myers Squibb Co (BMY) Suffers Heavy Dose of Disappointment - (NYSE:BMY) - October 10 at 3:47 PM logoUPDATE 1-Bristol lung-cancer setback puts rival Merck drug in driver seat (NYSE:BMY) - October 10 at 3:28 PM logoAn Extended Trial for Bristol-MyersSquibb (NYSE:BMY) - October 10 at 2:51 PM


Bristol-Myers Squibb (NYSE:BMY) Chart for Friday, October, 21, 2016

Last Updated on 10/21/2016 by Staff